Irritable bowel syndrome is characterized by the presence of chronic, recurrent abdominal pain, alterations in bowel habits, and abdominal distension. The medical diagnosis is made using the Rome IV criteria. There are three IBS phenotypes: diarrhea-predominant, constipation-predominant, and mixed.

A sample of 100 people will be supplemented, with 50 participants consuming the nutraceutical gel and the remaining 50 receiving a placebo supplement. The supplementation period lasts 14 days, during which severity questionnaires and the Bristol Stool Scale will be administered on Day 0, Day 7, and Day 14. Additionally, to assess biomarkers, biochemical tests for PCR, calprotectin, and fecal lactoferrin will be conducted.

Inclusion Criteria:

• Must be over 18 years old.
• Be an employee or beneficiary of UANL.
• Have gastrointestinal alterations (diarrhea, constipation, etc.) that suggest the presence of irritable bowel syndrome.
• Not be under any medical treatment.

Exclusion Criteria:

• Being under medical treatment.
• Not having gastrointestinal alterations much as diarrhea, constipation, etc.
• being under 18 years old.
• Not being an employee or beneficiary of UANL.

Male or female.

The personal data, including biochemical data of the participants, will not be shared for use in other clinical trials or for additional research purposes.

For the purposes of the study, it was decided to use a double-blind method, where neither the investigator nor the patient knows which treatment is the nutraceutical and which is the placebo. To achieve this, the team was responsible for mixing the treatment packages to allow for proper distribution.